Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Considerations for the use of imaging tools for phase II treatment trials in oncology Shankar LK; Van den Abbeele A; Yap J; Benjamin R; Scheutze S; Fitzgerald TJClin Cancer Res 2009[Mar]; 15 (6): 1891-7In the context of assessing tumor response, imaging tools have the potential to play a vital role in phase II and III treatment trials. If the imaging test is able to predict potential phase III success in a reliable fashion, it would be a useful tool in phase II trial design as it may provide for a more rapid and timely response assessment. The benefits and challenges of using anatomic imaging measures as well as the promising molecular imaging measures, primarily fluorodeoxyglucose-positron emission tomography, are discussed here. The general issues related to successful implementation of advanced imaging in the context of phase II treatment trials are discussed.|*Fluorodeoxyglucose F18[MESH]|Clinical Trials, Phase II as Topic/*methods[MESH]|Endpoint Determination[MESH]|Gastrointestinal Stromal Tumors/diagnostic imaging/drug therapy[MESH]|Humans[MESH]|Neoplasms/diagnostic imaging/*drug therapy[MESH]|Positron-Emission Tomography/*methods[MESH]|Quality Assurance, Health Care[MESH]|Sarcoma/diagnostic imaging/drug therapy[MESH] |